MARLOW & NOTTINGHAM, UK. — April 8, 2019 – UK microbiome therapeutics company CHAIN Biotechnology has appointed two new non-executive directors, Dr Nel Moore and Dr Robert Haigh to the Board. Dr Nel Moore has considerable experience in drug development with a track record taking therapeutics to market as former Global Product Vice President at […]
CHAIN has been awarded two grants to support its therapeutic delivery platform from Innovate UK (IUK), the UK’s innovation agency. The grant-funded projects will focus on the development and testing of two new biotherapeutics using CHAIN’s proprietary delivery platform CADDTM. The projects build on successful IUK funded projects that were used to develop and validate […]
NOTTINGHAM, UK. — January 9th, 2019 — CHAIN has joined EuropaBio as a full member after placing runner-up in the Biotech SME Awards announced in November. As part of this membership, CHAIN gains access to EuropaBio’s network and will receive updates from working groups operating in diverse areas such as IP, regulatory policy and personalised […]
CHAIN Biotechnology Ltd develops Clostridium-based microbial technology for high-value healthcare products. We produce novel 2nd generation live biotherapeutic products for chronic gut-related diseases.
We target inflammatory bowel disease with a focus on Ulcerative Colitis. Our live biotherapeutic platform is based on a Clostridium strain engineered to produce the anti-inflammatory β-hydroxybutyrate.